Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6231)	4/28/2002 12:02:04 PM
From: Robohogs	Respond to of 52153

The ICN expiration surprised me too (knew it was soon but not sure on exact timing) - that was the reason I posted the table - it came from Thestreet.com. Thanks. Jon

To: Biomaven who wrote (6231)	4/28/2002 5:14:56 PM
From: rkrw	Read Replies (2) \| Respond to of 52153

<<Is the ICN Intron patent really up in 2002? >> Considering Roche's pegasys version of ifn alpha is near fda approval and high profile, I suppose the expiration is no secret. ICN controls ribavirin which is part of the rebotol combination, so technically unless I'm missing something big, intron A is not ICN's patent to expire.